Results

Total Results: 1,571 records

Showing results for "discussed".

61. Disposition of Comments Report for CER 132 Combination Therapy Versus Intensification of Statin Monotherapy: An Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/high-cholestorol-medicines-update_disposition-comments.pdf
    September 01, 2014 - For reasons that will be discussed below, under “PG5”, we believe this statement is not supported by … For reasons discussed above, we recommend that the authors define this term. … We have discussed the duration of protocol in limitations section of the Discussion. … We have discussed the new (Nov 2013) cholesterol lowering guidelines in the report. … This should be discussed in the document.

62. Ch 6-User-Guide-To-Ocer 130129 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/ch_6-user-guide-to-ocer_130129.pdf
    October 30, 2012 - Responsiveness is another property usually discussed in the context of patient-reported outcomes (PROs … Issues of misclassification and considerations in reducing this type of error are discussed further … Feasibility considerations sometimes dictate the use of intermediate endpoints, which are discussed … Utility measures are discussed further in the following section. … Notwithstanding the limitations of intermediate endpoints (discussed in a preceding section), one of

63. Evidence-based Practice Center Systematic Review Protocol - Management of Infantile Epilepsies (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-252-infantile-epilepsies-disposition-comments.pdf
    October 25, 2022 - One included RCT compared valproate alone to valproate+levetiracetam, and we discussed that study at … Since this was the only study using valproate, we discussed the results within the levetiracetam section … The revision adds mention of valproate and that its results are discussed in the levetiracetam section … The other distinction is by pathology, and that could be at least discussed; but the big distinction … those risks are up front and in long run better than risk of SUDEP or accidental death (not really discussed

64. Disposition of Comments Report for Strategies To Reduce Cesarean Birth in Low-Risk Women (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cesarean-birth-2010_disposition-comments.pdf
    January 01, 2010 - This is only discussed in the detailed synthesis. … For example, Cochrane results are discussed in the Amniotomy and Active Management sections but not … The inclusion criteria that were discussed by the TEP are not reflected in this report. … The issue of lack of power to detect harm should be highlighted and discussed in more detail. … This topic is also discussed in the comment above. EC Clarity & Usability c.

65. Disposition of Comments for CER 170 Cultural Competence Health Disparities (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/cultural-competence_disposition-comments.pdf
    January 01, 2020 - Leslie Hausmann Disability this is a lot more detail than what was provided on studies discussed … Thank you, we discussed this distinction in more depth in Chapter 1. … Thank you, in this case consensus adjudication refers to a process by which the authors discussed the … TEP 1 General The authors also have not discussed or cited much of the important and extensive research … This is discussed in more detail below. Thank you for the comment.

66. CER 220: Disposition of Comments Report for Comparative Effectiveness of Analgesics To Reduce Acute Pain in the Prehospital Setting (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-220-disposition-comments-analgesics-prehospital-setting.pdf
    September 03, 2019 - not address use of nonpharmacologic pain management strategies and state that the guideline panel discussed … During protocol development, clinically important differences were discussed with the Technical Expert … During protocol development, clinically important differences were discussed with the Technical Expert … During protocol development, clinically important differences were discussed with the Technical Expert … Public Reviewer #3, Kalpit Shah, AAOS - EBVQ Committee General Ketamine discussed as an alternative

67. CER 215 Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-215-depression-older-adults-comments.pdf
    March 28, 2019 - American Psychiatric Association Introduction On p. 4, in the 2nd paragraph, the Beers Criteria are discussed … data are in Appendix C, I would like to see them included in some format in the Results section, then discussed … Peer reviewer #4 Results Here are some other studies that were discussed among Beers Criteria members … Limitations are adequately discussed, and needs for future research are clearly stated. … Peer reviewer #6 Discussion Limitations: Please include issues discussed in the general remarks regarding

68. Disposition of Comments for Efficacy and Safety of Screening for Postpartum Depression (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/depression-postpartum-screening_disposition-comments.pdf
    May 01, 2013 - The search strategies (including specific databases to be searched) were discussed and confirmed with … Possible use of CINAHL was discussed at that time; the TEP agreed that the included databases were … Yes, it is good your report discussed adequate systems. … As discussed in the report, the definition of “reasonably high specificity” is not clear. … Possible use of CINAHL was discussed at that time; the TEP agreed that the included databases were

69. Partial Breast Irradiation for Breast Cancer (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/partial-breast-irradiation-disposition-comments.pdf
    January 31, 2023 - fraction, there may be less gains in reducing acute toxicity when comparing with hypofractioned WBRT (as discussed … patients at very low risk of recurrence (with all the caveats of risk & benefit & patient preference discussed

70. Disposition of Comments Report for Decision Aids for Cancer Screening and Treatment (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cancer-decision-support-tools_disposition-comments.pdf
    December 23, 2014 - Disagreements were discussed and analyzed to clarify screening criteria. … Peer Reviewer #1 Methods The possibility of, or conditions for, performing meta-analyses is not discussed … TEP Reviewer #2 Results I would like to see some additional explanation provided about the study discussed … Discussion/ Conclusion The methodological weaknesses in this review should either be corrected or discussed … clarifications provided resolve any … and show that the suggested alternatives were extensively discussed

71. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/diabetes-update-2015_disposition-comments.pdf
    January 01, 2015 - I also am hoping that the long terms risks of hypoglycemia are discussed more in the full text. it … We have discussed this issue in our limitations section of the report. … We have discussed patient preference as well as cost briefly as potential drivers. … Risk differences are also discussed in the Discussion of the main report and Executive Summary when … In future, other alternatives could be discussed.

72. Disposition of Comments_Systematic Review_Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder: 2024 Update of the Evidence Base for the PTSD Trials Standardized Data Repository (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/ptsd-pharm-non-pharm-treatment-update-disposition-comments.pdf
    August 28, 2024 - We agree that there is a strong need for better reporting of these variables, and have discussed

73. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-disease-ace-inhibitor-arb-disposition.pdf
    March 10, 2010 - Introduction Different etiologies of stroke are not discussed since these could be impacted differently … If there are differences between ARBs, and these differences are to be discussed within the comparative … As we have discussed in our review, these trials were not be combined with trials such as HOPE and

74. Disposition of Comments Report for Acute Migraine Treatment in Emergency Settings (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/migraine-emergency_disposition-comments.pdf
    November 27, 2012 - We have discussed the inclusion of non-EDs settings in the applicability sections of the executive … Peer Reviewer #2 Executive summary In the Executive Summary, drugs are loosely discussed in terms … Since this is not a meta-analysis then outcomes from all trials could have been discussed. … the paper, after reading it, I was still not sure what the authors meant in text and graphs that discussed … Peer Reviewer #2 Results In the results section (page 30), the neuroleptics are again discussed,

75. CER 205 Disposition of Comments for Physiologic Predictors of Severe Injury: A Systematic Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-205-predictors-trauma-care-disposition-comments.pdf
    April 01, 2018 - We considered several different approaches and discussed them and decided to focus on measures that … cost benefit re: use of point of care lab testing for lactate/other potential labs in field should be discussed

76. Comparative Effectiveness Review Disposition of Comments Report (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/bundled-payments-quality-effects_disposition-comments.pdf
    August 24, 2012 - Abstract It wasn't clear in the summary (and elsewhere in the report) whether all of the results discussed … This could be discussed in more detail. … Also, cost-sharing and limits on coverage are discussed for some settings, but not others. … In fact, the only objective discussed was assessing the fiscal benefits of bundled payments. … We have emphasized the limitations of the report as discussed in responses to other comments above.

77. Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers; Long-Term Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/adhd_disposition-comments.pdf
    October 01, 2011 - p.1- remaining issues, prg.1, Discussed in Limitations section ES-16 to ES-18 and Limitations pp174 … {12105} is an included article MTA discussed in another section Archived: This report is greater … Discussed in Limitations section P 121 of 278 Peer Reviewer #4 Results On pp. 108—109 of 255, … No response required Peer Reviewer #6 Discussion Page 147 of 255: as already discussed – incorrect … Peer Reviewer #7 Discussion p 132 L-50 Results of review of these studies are discussed below.

78. CER 210: Disposition of Comments for Breastfeeding Programs and Policies, Breastfeeding Uptake, and Maternal Health Outcomes in Developed Countries (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-210-breastfeeding-disposition-comments.pdf
    January 01, 2020 - This is not discussed in the executive summary and is not even mentioned in the text until page 124 … Section Comment Response TEP Reviewer 1 Discussion/ Conclusion One of the biggest limitations not discussed … tables in the executive summary would greatly benefit from the insertion of references for each of the discussed … In this review, I see a few studies discussed in conjunction with other interventions (e.g.

79. Disposition of Comments for CER 172 Clostridium Difficile Diagnosis Prevention Treatment (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/c-difficile-update_disposition-comments.pdf
    March 29, 2016 - Reviewer #3 Results Second, the use of monoclonal antibodies directed against TcdA and TcdB could be discussed … Peer Reviewer #3 Discussion One area that is not discussed explicitly is some of the controversy regarding … This is discussed on page 24. … We have discussed some cost issues for fidaxomicin, as a newly approved but costly treatment. … are somewhat "telegraphic" and could be expanded to give the reader a better idea of what will be discussed

80. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-270-bimp-disposition-comments.pdf
    September 18, 2024 - One reviewer specifically noted that we discussed overall dropouts in the AE section, but such dropouts